ClinicalTrials.gg
Active, not recruitingNCT05587296OASIS-4Updated Jul 9, 2026Results posted

A Study to Learn More About How Well Elinzanetant Works and How Safe it is Compared to Placebo for the Treatment of Hot Flashes Caused by Anti-cancer Therapy in Women With, or at High Risk for Developing Hormone-receptor Positive Breast Cancer

A Phase 3 interventional study of Elinzanetant (BAY3427080) and Placebo in Vasomotor Symptoms Caused by Adjuvant Endocrine Therapy in Women With, or at High Risk for Developing Hormone-receptor Positive Breast Cancer and Hot Flashes, sponsored by Bayer. Active, not recruiting at 102 sites in 16 countries. Open to female participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-07-09.

Sponsored by Bayer · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
474
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 13 studies testing elinzanetant in Hot Flashes — none open to participants now, 1 under way, 1 of them phase 3. elinzanetant · Hot Flashes.

Enrollment
2nd of 13
474 · median 64
Started
2022
with 4 others
Phase 3
4 of 13
none open now
Registered
12th of 13
by date
Lead sponsor
13 of 13
Bayer

Among the 13 studies testing elinzanetant in Hot Flashes, this one is the 2nd largest by enrollment, is one of 5 that started in 2022, is one of 4 in phase 3, and was the 12th registered.

Hot Flashes

339 studies on the registry are indexed under Hot Flashes; 56 are open to participants now.

Browse Hot Flashes studies →

Open to participants now

None of the 13 studies testing elinzanetant in Hot Flashes is open now. The open studies under Hot Flashes, anywhere →

About elinzanetant

elinzanetant: first FDA approval 2025 (LYNKUET), first EMA approval 2025. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 36 Hot Flashes studies recruiting now, 13 (36%) set no upper age limit and 21 (58%) stop at 75 or younger; 2 take children under 18; 11 take healthy volunteers.

This study: 18 Years to 70 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 13 studies testing elinzanetant in Hot Flashes as a file.
02

Study summary

Researchers are looking for a better way to treat women with, or at high risk for developing hormone-receptor positive breast cancer, who have vasomotor symptoms (VMS), a condition of having hot flashes caused by anti-cancer therapy.

VMS, also called hot flashes, are very common medical problems in women with hormone-receptor (HR)-positive breast cancer, who are receiving anti-cancer therapy. HR-positive breast cancer is a type of breast cancer, which has hormone-receptors (proteins) for female sex hormones estrogen and/or progesterone. These hormone-receptors may attach to hormones like estrogen and progesterone and thereby help cancer cells to grow and to spread. Treatments that stop these hormones from attaching to these receptors are currently used to slow or stop the growth of HR-positive breast cancer.

It is already known that women with HR-positive breast cancer benefit from this treatment. However, hot flashes are common medical problems related to this therapy. They negatively affect quality of life of many women and may lead to discontinuation (stopping) of this therapy.

The study treatment, elinzanetant is being developed to treat hot flushes. It works by blocking a substance called neurokinin from sending signals to other parts of the body, which is thought to play a role in starting hot flashes.

The main purpose of this study is to learn more about how well elinzanetant helps to treat hot flashes caused by anti-cancer therapy in women with or at high risk for developing HR-positive breast cancer compared to placebo. A placebo is a treatment that looks like a medicine but does not have any medicine in it.

To answer this, the doctors will ask the participants to record information about their hot flashes before treatment start and at certain time points during the treatment in an electronic diary. The researchers will then assess possible average changes in number and severity of hot flashes after 4 and 12 weeks of treatment.

To see how safe elinzanetant is compared to placebo. The study will collect information about the number of participants who have medical problems after taking treatment.

The study participants will be randomly (by chance) assigned to 2 treatment groups, A and B. The participants from treatment group A will take elinzanetant. The participants from treatment group B will start with placebo and then switch to elinzanetant.

All participants will continue taking the anti-cancer therapy they have been using when entering the study.

Dependent on the treatment group, the participants will either take elinzanetant or placebo as capsules by mouth once a day. After 12 weeks, the participants who have initially received placebo will switch to take elinzanetant for the remaining 40 weeks.

Each participant will be in the study for approximately 62 weeks. The treatment duration in the study will be 52 weeks. There will be up to 12 visits to the study site and 6 phone calls in between. Participants who completed the 52 weeks treatment phase, will be offered to continue treatment for another up to 3.5 years.

During the study, the participants will:

  • record information about their hot flashes
  • answer questions about their quality of life and other symptoms.

The doctors and their study team will:

  • check the participants health and vital signs
  • take blood and urine samples
  • examine heart health using electrocardiogram (ECG)
  • examine pelvic organs like womb or ovaries using a trans vaginal ultrasound scan to see images of these organs
  • make images of the breast using x-ray (mammogram), a type of radiation that passes through the body to make images of the inside and/or by using ultrasound (if applicable)
  • check the health of the participant's cervix (neck of the womb) by taking a small sample of cells (smear test) for an analysis called cervical cytology (if applicable)
  • take an endometrial biopsy, a small piece of tissue from the lining of the womb (called the endometrium) for analysis.
  • ask the participants questions about what medicines they are taking and if they are having adverse events.

An adverse event is any medical problem that a participant has during a study. Doctors keep track of all adverse events that happen in studies, even if they do not think the adverse events might be related to the study treatments.

About 4 weeks after the participants take their last treatment, the study doctors and their team will check the participants' health.

03

Conditions studied

  • Vasomotor Symptoms Caused by Adjuvant Endocrine Therapy in Women With, or at High Risk for Developing Hormone-receptor Positive Breast Cancer
  • Hot Flashes

Browse trials for

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Females aged 18 to 70 years of age inclusive, at the time of signing the .
  • Women experiencing vasomotor symptoms (VMS) caused by endocrine therapy that they are expected to use for the duration of the study

    • Tamoxifen with or without the use of gonadotropin-releasing hormone (GnRH) analogues or
    • Aromatase inhibitors with or without the use of GnRH analogues
  • Women must have

    • a personal history of hormone-receptor positive breast cancer or
    • a high risk for developing breast cancer.
  • Participant has completed Hot Flash Daily Diary (HFDD) for at least 11 days during the two weeks preceding baseline visit, and participant has recorded at least 35 moderate to severe hot flash (HF) (including night-time HF) over the last 7 days that the HFDD was completed (assessed at the Baseline Visit).
  • use by [women except for women or Women of Non (WONCBP)] should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.

Exclusion criteria

Exclusion Criteria:

  • Initial diagnosis of hormone-receptor positive breast cancer (stage IV) or recurrence under endocrine therapy of hormone-receptor positive breast cancer.
  • Current or history (except complete remission for 5 years or more prior to signing ) of any , except for hormone-receptor positive breast cancer (Stage 0-III), basal and squamous cell skin tumors.
  • Surgery or non-surgical (e.g., chemotherapy, radiotherapy, immunotherapy) treatment for breast cancer within the last 3 months prior to signing informed consent (except use of tamoxifen, aromatase inhibitors, GnRH analogues).
  • Any prior or ongoing history of arrhythmias, heart block and either determined through clinical history or on (ECG) evaluation.
  • Any active ongoing condition that could cause difficulty in interpreting VMS such as: infection that could cause pyrexia, pheochromocytoma, carcinoid syndrome.
  • Any unexplained vaginal bleeding.
  • Mammogram with clinically relevant malignant or suspicious findings that will require surgery, radiotherapy or chemotherapy as per local guidelines (mammogram should not be older than 12 months prior to signing informed consent). If a mammogram is not possible after partial mastectomy an ultrasound could be performed instead.
  • Disordered proliferative endometrium, endometrial hyperplasia, polyp, or endometrial cancer diagnosed based on endometrial during screening.
  • Current arterial or venous vascular event (e.g., Myocardial infarction (MI), (TIA), stroke, deep vein thrombosis (DVT), i.e., within the last 6 months prior to signing informed consent.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
474 participants (actual)

Study arms

  • Experimental
    Elinzanetant (BAY3427080)

    Participants will receive 120 mg elinzanetant orally once daily.

    Drug: Elinzanetant (BAY3427080)

  • Placebo comparator
    Placebo

    Participants will receive matching placebo orally once daily for 12 weeks, followed by 120 mg elinzanetant orally once daily

    Drug: Elinzanetant (BAY3427080) · Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Mean Change in Frequency of Moderate to Severe Hot Flashes (HF) From Baseline to Week 4 (Assessed by Hot Flash Daily Diary [HFDD])

    Participants' assessments of HF were recorded electronically twice daily using the sponsor developed Hot Flash Daily Diary (HFDD). The HFDD was completed in the morning after waking up (morning diary) and each evening at bedtime (evening diary) on the hand-held device. The HFDD items assessed the number of mild, moderate, and severe HF experienced during the day and during the night. Mild HF was defined as a "sensation of heat without sweating", moderate HF was defined as a "sensation of heat with sweating, but able to continue activity", and severe HF was defined as a "sensation of heat with sweating, causing cessation (stopping) of activity". Mean daily frequency is calculated as total number of moderate to severe HF during that week divided by the total number of available days with data during that week.

    Time frame: Baseline to Week 4

  2. Mean Change in Frequency of Moderate to Severe HFs From Baseline to Week 12 (Assessed by HFDD)

    Participants' assessments of HF were recorded electronically twice daily using the sponsor developed Hot Flash Daily Diary (HFDD). The HFDD was completed in the morning after waking up (morning diary) and each evening at bedtime (evening diary) on the hand-held device. The HFDD items assessed the number of mild, moderate, and severe HF experienced during the day and during the night. Mild HF was defined as a "sensation of heat without sweating", moderate HF was defined as a "sensation of heat with sweating, but able to continue activity", and severe HF was defined as a "sensation of heat with sweating, causing cessation (stopping) of activity". Mean daily frequency is calculated as total number of moderate to severe HF during that week divided by the total number of available days with data during that week.

    Time frame: Baseline to Week 12

Secondary outcomes

  1. Mean Change in Severity of Moderate to Severe HF From Baseline to Week 4 (Assessed by HFDD).

    In the HFDD, the severity of HFs was categorized as: 1 = mild, 2 = moderate, and 3 = severe; therefore, a decrease in the HF severity score indicates an improvement. The mean daily severity during treatment was calculated for the available days as \[(1 x number of mild HF) + (2 x number of moderate HF) + (3 x number of severe HF)\] / (total number of mild, moderate and severe hot flashes on that day). When no HFs were reported for a particular day, the mean severity for that day was set to 0. The mean daily severity during baseline was calculated for the available days as \[(2 x number of moderate HF) + (3 x number of severe HF)\] / (total number of moderate to severe hot flashes on that day).

    Time frame: Baseline to Week 4

  2. Mean Change in Severity of Moderate to Severe HF From Baseline to Week 12 (Assessed by HFDD)

    In the HFDD, the severity of HFs was categorized as: 1 = mild, 2 = moderate, and 3 = severe; therefore, a decrease in the HF severity score indicates an improvement. The mean daily severity during treatment was calculated for the available days as \[(1 x number of mild HF) + (2 x number of moderate HF) + (3 x number of severe HF)\] / (total number of mild, moderate and severe hot flashes on that day). When no HFs were reported for a particular day, the mean severity for that day was set to 0. The mean daily severity during baseline was calculated for the available days as \[(2 x number of moderate HF) + (3 x number of severe HF)\] / (total number of moderate to severe hot flashes on that day).

    Time frame: Baseline to Week 12

  3. Mean Change in Frequency of Moderate to Severe HF From Baseline to Week 1 (Assessed by HFDD)

    Participants' assessments of HF were recorded electronically twice daily using the sponsor developed Hot Flash Daily Diary (HFDD). The HFDD was completed in the morning after waking up (morning diary) and each evening at bedtime (evening diary) on the hand-held device. The HFDD items assessed the number of mild, moderate, and severe HF experienced during the day and during the night. Mild HF was defined as a "sensation of heat without sweating", moderate HF was defined as a "sensation of heat with sweating, but able to continue activity", and severe HF was defined as a "sensation of heat with sweating, causing cessation (stopping) of activity". Mean daily frequency is calculated as total number of moderate to severe HF during that week divided by the total number of available days with data during that week.

    Time frame: Baseline to Week 1

  4. Mean Change in Frequency of Moderate to Severe HF From Baseline Over Time (Assessed by HFDD)

    Participants' assessments of HF were recorded electronically twice daily using the sponsor developed Hot Flash Daily Diary (HFDD). The HFDD was completed in the morning after waking up (morning diary) and each evening at bedtime (evening diary) on the hand-held device. The HFDD items assessed the number of mild, moderate, and severe HF experienced during the day and during the night. Mild HF was defined as a "sensation of heat without sweating", moderate HF was defined as a "sensation of heat with sweating, but able to continue activity", and severe HF was defined as a "sensation of heat with sweating, causing cessation (stopping) of activity". Mean daily frequency is calculated as total number of moderate to severe HF during that week divided by the total number of available days with data during that week.

    Time frame: Baseline to Week 50

  5. Mean Change in Patient-reported Outcomes Measurement Information System Sleep Disturbance Short Form 8b (PROMIS SD SF 8b) Total Score From Baseline to Week 12

    The PROMIS SD SF 8b includes 8 items assessing sleep disturbance over the past 7 days. Items assess sleep quality, sleep depth and restoration associated with sleep, perceived difficulties with getting to sleep or staying asleep and perceptions of the adequacy of and satisfaction with sleep. Participants respond to the items on a 5-point scale from "not at all", "never" or "very poor" to "very much", "always" or "very good". Four of the items are scored reversely. Individual item scores are aggregated to total raw scores which range from 8 to 40. Total raw scores are converted into T-scores for comparison with population norms, with a mean of 50 and standard deviation of 10. T-scores range from 28.9 to 76.5. For both raw and T-scores higher scores indicate greater severity of sleep disturbance. According to available score cut points from PROMIS developers, T-scores can be interpreted as indicating mild (55-59), moderate (60-69), or severe (\>70) sleep disturbance.

    Time frame: Baseline to Week 12

  6. Mean Change in Menopause Specific Quality of Life Scale (MENQOL) Total Score From Baseline to Week 12

    The MENQOL questionnaire is comprised of 29 items assessing the presence of menopausal symptoms and the impact of menopause on health-related quality of life over the past week. The items assess four domains of symptoms and functioning: VMS, psychosocial functioning, physical functioning, and sexual functioning. For each item, the participant indicates if they have experienced the symptom (yes/no). If participants select yes, participants rate how bothered they were by the symptom using a six-point verbal descriptor scale, with response options ranging from 0 'not at all bothered' to 6 'extremely bothered'. Based on the individual responses, item scores, domain scores, and a total MENQOL score are calculated. Each score ranges from 1-8, higher scores indicate greater bother. For a MENQOL total score, the aggregated mean of the mean domain scores is calculated.

    Time frame: Baseline to Week 12

07

Results

Posted Oct 29, 2025

Participant flow

The study was conducted at 97 study centers, predominantly in Europe and at several centers in Canada, Israel, Kazakhstan and United Kingdom starting 14-Oct-2022 (first participant first visit), reaching primary completion on 29-Jan-2024.

Participant flow — Overall Study
MilestoneElinzanetant (BAY3427080)Placebo - Elinzanetant (BAY3427080)
Started316158
Completed262133
Not completed5425
Withdrew: Adverse event157
Withdrew: Lack of efficacy20
Withdrew: Lost to follow-up10
Withdrew: Withdrawal by subject144
Withdrew: Miscellaneous36
Withdrew: Did not complete study treatment but completed post-treatment phase/follow-up198

Outcome measures

PrimaryMean Change in Frequency of Moderate to Severe Hot Flashes (HF) From Baseline to Week 4 (Assessed by Hot Flash Daily Diary [HFDD])

Participants' assessments of HF were recorded electronically twice daily using the sponsor developed Hot Flash Daily Diary (HFDD). The HFDD was completed in the morning after waking up (morning diary) and each evening at bedtime (evening diary) on the hand-held device. The HFDD items assessed the number of mild, moderate, and severe HF experienced during the day and during the night. Mild HF was defined as a "sensation of heat without sweating", moderate HF was defined as a "sensation of heat with sweating, but able to continue activity", and severe HF was defined as a "sensation of heat with sweating, causing cessation (stopping) of activity". Mean daily frequency is calculated as total number of moderate to severe HF during that week divided by the total number of available days with data during that week.

Time frame:
Baseline to Week 4
Reported as:
Mean · hot flashes per day
Mean Change in Frequency of Moderate to Severe Hot Flashes (HF) From Baseline to Week 4 (Assessed by Hot Flash Daily Diary [HFDD])
hot flashes per dayElinzanetant (BAY3427080)Placebo - Elinzanetant (BAY3427080)
Baseline11.41 ± 6.8911.52 ± 6.43
Change from Baseline Week 4-6.51 ± 6.13-3.04 ± 5.04
Statistical analysis
  • Elinzanetant (BAY3427080) vs Placebo - Elinzanetant (BAY3427080) · Mixed model repeated measures (MMRM) · p = <0.0001 (One-sided. A multiplicity adjustment strategy was defined using the hierarchical testing strategy, controlling the overall type I error rate at a one-sided alpha level of 0.025 for confirmatory statistical superiority testing.) · Diffrence in least squares (ls) means: -3.48
PrimaryMean Change in Frequency of Moderate to Severe HFs From Baseline to Week 12 (Assessed by HFDD)

Participants' assessments of HF were recorded electronically twice daily using the sponsor developed Hot Flash Daily Diary (HFDD). The HFDD was completed in the morning after waking up (morning diary) and each evening at bedtime (evening diary) on the hand-held device. The HFDD items assessed the number of mild, moderate, and severe HF experienced during the day and during the night. Mild HF was defined as a "sensation of heat without sweating", moderate HF was defined as a "sensation of heat with sweating, but able to continue activity", and severe HF was defined as a "sensation of heat with sweating, causing cessation (stopping) of activity". Mean daily frequency is calculated as total number of moderate to severe HF during that week divided by the total number of available days with data during that week.

Time frame:
Baseline to Week 12
Reported as:
Mean · hot flashes per day
Mean Change in Frequency of Moderate to Severe HFs From Baseline to Week 12 (Assessed by HFDD)
hot flashes per dayElinzanetant (BAY3427080)Placebo - Elinzanetant (BAY3427080)
Baseline11.41 ± 6.8911.52 ± 6.43
Change from Baseline week 12-7.76 ± 6.17-4.20 ± 6.06
Statistical analysis
  • Elinzanetant (BAY3427080) vs Placebo - Elinzanetant (BAY3427080) · MMRM · p = <0.0001 (One-sided. A multiplicity adjustment strategy was defined using the hierarchical testing strategy, controlling the overall type I error rate at a one-sided alpha level of 0.025 for confirmatory statistical superiority testing.) · Difference in least squares means: -3.38
SecondaryMean Change in Severity of Moderate to Severe HF From Baseline to Week 4 (Assessed by HFDD).

In the HFDD, the severity of HFs was categorized as: 1 = mild, 2 = moderate, and 3 = severe; therefore, a decrease in the HF severity score indicates an improvement. The mean daily severity during treatment was calculated for the available days as \[(1 x number of mild HF) + (2 x number of moderate HF) + (3 x number of severe HF)\] / (total number of mild, moderate and severe hot flashes on that day). When no HFs were reported for a particular day, the mean severity for that day was set to 0. The mean daily severity during baseline was calculated for the available days as \[(2 x number of moderate HF) + (3 x number of severe HF)\] / (total number of moderate to severe hot flashes on that day).

Time frame:
Baseline to Week 4
Reported as:
Mean · score*hot flashes/total of hot flashes
Mean Change in Severity of Moderate to Severe HF From Baseline to Week 4 (Assessed by HFDD).
score*hot flashes/total of hot flashesElinzanetant (BAY3427080)Placebo - Elinzanetant (BAY3427080)
Baseline2.49 ± 0.242.49 ± 0.22
Change from Baseline week 4-0.73 ± 0.60-0.43 ± 0.43
SecondaryMean Change in Severity of Moderate to Severe HF From Baseline to Week 12 (Assessed by HFDD)

In the HFDD, the severity of HFs was categorized as: 1 = mild, 2 = moderate, and 3 = severe; therefore, a decrease in the HF severity score indicates an improvement. The mean daily severity during treatment was calculated for the available days as \[(1 x number of mild HF) + (2 x number of moderate HF) + (3 x number of severe HF)\] / (total number of mild, moderate and severe hot flashes on that day). When no HFs were reported for a particular day, the mean severity for that day was set to 0. The mean daily severity during baseline was calculated for the available days as \[(2 x number of moderate HF) + (3 x number of severe HF)\] / (total number of moderate to severe hot flashes on that day).

Time frame:
Baseline to Week 12
Reported as:
Mean · score*hot flashes/total of hot flashes
Mean Change in Severity of Moderate to Severe HF From Baseline to Week 12 (Assessed by HFDD)
score*hot flashes/total of hot flashesElinzanetant (BAY3427080)Placebo - Elinzanetant (BAY3427080)
Baseline2.49 ± 0.242.49 ± 0.22
Change from Baseline week 12-0.98 ± 0.72-0.53 ± 0.60
SecondaryMean Change in Frequency of Moderate to Severe HF From Baseline to Week 1 (Assessed by HFDD)

Participants' assessments of HF were recorded electronically twice daily using the sponsor developed Hot Flash Daily Diary (HFDD). The HFDD was completed in the morning after waking up (morning diary) and each evening at bedtime (evening diary) on the hand-held device. The HFDD items assessed the number of mild, moderate, and severe HF experienced during the day and during the night. Mild HF was defined as a "sensation of heat without sweating", moderate HF was defined as a "sensation of heat with sweating, but able to continue activity", and severe HF was defined as a "sensation of heat with sweating, causing cessation (stopping) of activity". Mean daily frequency is calculated as total number of moderate to severe HF during that week divided by the total number of available days with data during that week.

Time frame:
Baseline to Week 1
Reported as:
Mean · hot flashes per day
Mean Change in Frequency of Moderate to Severe HF From Baseline to Week 1 (Assessed by HFDD)
hot flashes per dayElinzanetant (BAY3427080)Placebo - Elinzanetant (BAY3427080)
Baseline11.41 ± 6.8911.52 ± 6.43
Change from baseline week 1-4.04 ± 5.11-1.76 ± 3.83
SecondaryMean Change in Frequency of Moderate to Severe HF From Baseline Over Time (Assessed by HFDD)

Participants' assessments of HF were recorded electronically twice daily using the sponsor developed Hot Flash Daily Diary (HFDD). The HFDD was completed in the morning after waking up (morning diary) and each evening at bedtime (evening diary) on the hand-held device. The HFDD items assessed the number of mild, moderate, and severe HF experienced during the day and during the night. Mild HF was defined as a "sensation of heat without sweating", moderate HF was defined as a "sensation of heat with sweating, but able to continue activity", and severe HF was defined as a "sensation of heat with sweating, causing cessation (stopping) of activity". Mean daily frequency is calculated as total number of moderate to severe HF during that week divided by the total number of available days with data during that week.

Time frame:
Baseline to Week 50
Reported as:
Mean · hot flashes per day
Mean Change in Frequency of Moderate to Severe HF From Baseline Over Time (Assessed by HFDD)
hot flashes per dayElinzanetant (BAY3427080)Placebo - Elinzanetant (BAY3427080)
Baseline11.41 ± 6.8911.52 ± 6.43
Change from baseline to Week 1-4.04 ± 5.11-1.76 ± 3.83
Change from baseline to Week 2-5.55 ± 5.88-2.78 ± 4.31
Change from baseline to Week 3-6.19 ± 5.94-2.96 ± 4.82
Change from baseline to Week 4-6.51 ± 6.13-3.04 ± 5.04
Change from baseline to Week 5-6.84 ± 5.92-3.35 ± 5.06
Change from baseline to Week 6-7.04 ± 6.20-3.69 ± 5.37
Change from baseline to Week 7-7.32 ± 6.05-3.96 ± 5.60
Change from baseline to Week 8-7.45 ± 6.25-4.02 ± 5.53
Change from baseline to Week 9-7.49 ± 6.29-4.00 ± 5.64
Change from baseline to Week 10-7.48 ± 6.03-3.88 ± 5.82
Change from baseline to Week 11-7.74 ± 6.16-4.08 ± 5.94
Change from baseline to Week 12-7.76 ± 6.17-4.20 ± 6.06
Change from baseline to Week 25-8.98 ± 6.12-9.60 ± 6.04
Change from baseline to Week 26-8.93 ± 6.13-9.55 ± 6.14
Change from baseline to Week 35-9.05 ± 6.16-9.30 ± 6.23
Change from baseline to Week 36-8.94 ± 6.15-9.13 ± 6.25
Change from baseline to Week 49-8.77 ± 5.89-9.02 ± 6.17
Change from baseline to Week 50-8.72 ± 6.22-8.90 ± 6.01
SecondaryMean Change in Patient-reported Outcomes Measurement Information System Sleep Disturbance Short Form 8b (PROMIS SD SF 8b) Total Score From Baseline to Week 12

The PROMIS SD SF 8b includes 8 items assessing sleep disturbance over the past 7 days. Items assess sleep quality, sleep depth and restoration associated with sleep, perceived difficulties with getting to sleep or staying asleep and perceptions of the adequacy of and satisfaction with sleep. Participants respond to the items on a 5-point scale from "not at all", "never" or "very poor" to "very much", "always" or "very good". Four of the items are scored reversely. Individual item scores are aggregated to total raw scores which range from 8 to 40. Total raw scores are converted into T-scores for comparison with population norms, with a mean of 50 and standard deviation of 10. T-scores range from 28.9 to 76.5. For both raw and T-scores higher scores indicate greater severity of sleep disturbance. According to available score cut points from PROMIS developers, T-scores can be interpreted as indicating mild (55-59), moderate (60-69), or severe (\>70) sleep disturbance.

Time frame:
Baseline to Week 12
Reported as:
Mean · T-Score
Mean Change in Patient-reported Outcomes Measurement Information System Sleep Disturbance Short Form 8b (PROMIS SD SF 8b) Total Score From Baseline to Week 12
T-ScoreElinzanetant (BAY3427080)Placebo - Elinzanetant (BAY3427080)
Baseline60.60 ± 6.3360.74 ± 6.80
Change from Baseline week 12-10.55 ± 8.20-4.06 ± 7.35
Statistical analysis
  • Elinzanetant (BAY3427080) vs Placebo - Elinzanetant (BAY3427080) · MMRM · p = <0.0001 (One-sided. A multiplicity adjustment strategy was defined using the hierarchical testing strategy, controlling the overall type I error rate at a one-sided alpha level of 0.025 for confirmatory statistical superiority testing.) · Difference in least squares means: -6.12
SecondaryMean Change in Menopause Specific Quality of Life Scale (MENQOL) Total Score From Baseline to Week 12

The MENQOL questionnaire is comprised of 29 items assessing the presence of menopausal symptoms and the impact of menopause on health-related quality of life over the past week. The items assess four domains of symptoms and functioning: VMS, psychosocial functioning, physical functioning, and sexual functioning. For each item, the participant indicates if they have experienced the symptom (yes/no). If participants select yes, participants rate how bothered they were by the symptom using a six-point verbal descriptor scale, with response options ranging from 0 'not at all bothered' to 6 'extremely bothered'. Based on the individual responses, item scores, domain scores, and a total MENQOL score are calculated. Each score ranges from 1-8, higher scores indicate greater bother. For a MENQOL total score, the aggregated mean of the mean domain scores is calculated.

Time frame:
Baseline to Week 12
Reported as:
Mean · Scores on a scale
Mean Change in Menopause Specific Quality of Life Scale (MENQOL) Total Score From Baseline to Week 12
Scores on a scaleElinzanetant (BAY3427080)Placebo - Elinzanetant (BAY3427080)
Baseline4.82 ± 1.174.77 ± 1.25
Change from Baseline week 12-1.30 ± 1.11-0.53 ± 1.15
Statistical analysis
  • Elinzanetant (BAY3427080) vs Placebo - Elinzanetant (BAY3427080) · MMRM · p = <0.0001 (One-sided. A multiplicity adjustment strategy was defined using the hierarchical testing strategy, controlling the overall type I error rate at a one-sided alpha level of 0.025 for confirmatory statistical superiority testing.) · Difference in last squares means: -0.68

Adverse events

Collected over From signing the ICF through study complition, approximately 14 months. Non-serious events are listed at a 0.05% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Elinzanetant 120mg Week 1-120/315 (0%)8/315 (2.5%)145/315 (46%)
Placebo Week 1-120/158 (0%)1/158 (0.6%)61/158 (38.6%)
Elinzanetant 120mg Week 13-260/294 (0%)8/294 (2.7%)72/294 (24.5%)
Placebo - Elinzanetant 120mg Week 13-260/150 (0%)4/150 (2.7%)38/150 (25.3%)
Elinzanetant 120mg Week 1-260/465 (0%)18/465 (3.9%)211/465 (45.4%)
Elinzanetant 120mg Week 27-520/409 (0%)18/409 (4.4%)73/409 (17.8%)
Elinzanetant 120mg Week 1-520/465 (0%)33/465 (7.1%)241/465 (51.8%)
Most frequent serious events
Showing 10 of 36
Most frequent serious events
EventElinzanetant 120mg Week 1-12Placebo Week 1-12Elinzanetant 120mg Week 13-26Placebo - Elinzanetant 120mg Week 13-26Elinzanetant 120mg Week 1-26Elinzanetant 120mg Week 27-52Elinzanetant 120mg Week 1-52
COVID-19Infections and infestations0/3150/1580/2941/1501/4650/4091/465
ConcussionInjury, poisoning and procedural complications0/3150/1580/2941/1501/4650/4091/465
HypokalaemiaMetabolism and nutrition disorders0/3150/1580/2941/1501/4650/4091/465
Breast cancer recurrentNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/3150/1580/2941/1501/4650/4091/465
Ligament operationSurgical and medical procedures0/3151/1580/2940/1500/4650/4090/465
Uterine polypReproductive system and breast disorders0/3150/1580/2940/1500/4652/4092/465
Metastases to liverNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/3150/1581/2940/1502/4650/4092/465
Breast reconstructionSurgical and medical procedures1/3150/1580/2940/1501/4651/4092/465
CataractEye disorders0/3150/1581/2940/1501/4651/4091/465
Bile duct stoneHepatobiliary disorders0/3150/1581/2940/1501/4650/4091/465
Most frequent other events
Showing 10 of 12
Most frequent other events
EventElinzanetant 120mg Week 1-12Placebo Week 1-12Elinzanetant 120mg Week 13-26Placebo - Elinzanetant 120mg Week 13-26Elinzanetant 120mg Week 1-26Elinzanetant 120mg Week 27-52Elinzanetant 120mg Week 1-52
HeadacheNervous system disorders30/31520/15813/2947/15048/46511/40956/465
ArthralgiaMusculoskeletal and connective tissue disorders20/31510/15819/2946/15042/46515/40952/465
SomnolenceNervous system disorders34/3156/1584/2945/15042/4651/40942/465
FatigueGeneral disorders30/3158/1587/2945/15041/4653/40943/465
Depression rating scale score increasedInvestigations21/31513/1581/2940/15022/4652/40926/465
NasopharyngitisInfections and infestations12/3155/1589/2948/15028/4659/40937/465
DiarrhoeaGastrointestinal disorders16/3153/1586/2944/15025/4657/40932/465
COVID-19Infections and infestations4/3154/1589/2944/15017/46513/40932/465
NauseaGastrointestinal disorders19/31510/1586/2945/15028/4653/40929/465
Back painMusculoskeletal and connective tissue disorders10/3157/1585/2942/15016/46514/40929/465

Baseline characteristics

Age, Continuous
Age, Continuous(years)Elinzanetant (BAY3427080)Placebo - Elinzanetant (BAY3427080)Total
Mean50.8 ± 7.551.5 ± 6.751.0 ± 7.3
Sex: Female, Male
Sex: Female, Male(Participants)Elinzanetant (BAY3427080)Placebo - Elinzanetant (BAY3427080)Total
Female316158474
Male000
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Elinzanetant (BAY3427080)Placebo - Elinzanetant (BAY3427080)Total
Hispanic or Latino7512
Not Hispanic or Latino289143432
Unknown or Not Reported201030
08

Study locations

102 sites
  • AKH Wien | Allg. Gynaekologie & gynaekologische Onkologie
    Vienna, Burgenland 7000, Austria
  • MedUni Innsbruck | Brust Gesundheit Zentrum
    Vienna, State of Vienna 1140, Austria
  • Medical University of Graz | Division of Gynecology and Obstetrics
    Salzburg, 5020, Austria
  • ZAS Augustinus - Gynaecology department
    Wilrijk, Antwerpen 2610, Belgium
  • Hôpital Erasme/Erasmus Ziekenhuis
    Brussels, 1070, Belgium
  • CHU Saint-Pierre/UMC Sint-Pieter
    Bruxelles - Brussel, 1000, Belgium
  • CU Saint-Luc/UZ St-Luc
    Bruxelles - Brussel, 1200, Belgium
  • Ziekenhuis Oost-Limburg - Gynecology Department
    Genk, 3600, Belgium
  • Ghent University Hospital | Women's Clinic Department
    Ghent, 9000, Belgium
  • UZ Leuven Gasthuisberg
    Leuven, 3000, Belgium
  • Femicare vzw | Tienen, BE
    Tienen, 3300, Belgium
  • The Ottawa Hospital - Riverside Campus
    Ottawa, Ontario K1H 7W9, Canada
  • Centre Hospitalier de l'Universite de Montreal (CHUM) | Centre de Recherche
    Montreal, Quebec H2X 0A9, Canada
  • Lääkärikeskus Gyneko Oy
    Oulu, North Ostrobothnia 90100, Finland
  • Mehiläinen Kuopio
    Kuopio, Northern Savonia 70100, Finland
  • Tampere University Hospital, Tampereen yliopistollinen sairaala (TAYS)
    Tampere, Pirkanmaa 33520, Finland
  • Vaasa Central Hospital, Vaasan keskussairaala - Syöpätaudit
    Vaasa, Pohjanmaa 65130, Finland
  • Docrates Mehiläinen Syöpäsairaala
    Helsinki, Uusimaa 00180, Finland
  • UNICANCER - Centre Leon-Berard (CLB) - Medical oncology
    Lyon, Auvergne-Rhône-Alpes 69373, France
  • Centre Paul Strauss
    Strasbourg, Grand Est 67065, France
  • Institut Bergonie - Unicancer Nouvelle Aquitaine
    Bordeaux, New Aquitaine 33076, France
  • Centre de Lutte Contre le Cancer François Baclesse - Service Pathologie mammaire
    Caen, Normandy 14000, France
  • Institut du Cancer de Montpellier - Val d'Aurelle - Service Oncogynecologie et senologie
    Montpellier, Occitanie 34090, France
  • ICO Site Paul Papin - Angers - Service Oncologie
    Angers, Pays de la Loire Region 49100, France
  • Institut de Cancerologie Ouest - Saint-Herblain - Service gynecologie medicale
    Saint-Herblain, Pays de la Loire Region 44800, France
  • Hôpital Saint Louis
    Paris, Île-de-France Region 75010, France
  • Assistance Publique-Hopitaux de Paris (AP-HP) - Hopital Tenon - Gynecologie Obstetrique Medecine de la Reproduction
    Paris, Île-de-France Region 75020, France
  • Frauenarztpraxis Aurora
    Mannheim, Baden-Wurttemberg 68163, Germany
  • Eberhard-Karls-Universität Tübingen
    Tübingen, Baden-Wurttemberg 72076, Germany
  • Synexus Frankfurt Clinical Research Centre
    Frankfurt am Main, Hesse 60313, Germany
  • Klinische Forschung Hannover-Mitte GmbH
    Hanover, Lower Saxony 30159, Germany
  • Praxis Hr. Dr. S. Fiedler
    Aachen, North Rhine-Westphalia 52074, Germany
  • Evangelisches Krankenhaus Bergisch Gladbach - Gynäkologi
    Bergisch Gladbach, North Rhine-Westphalia 51465, Germany
  • Gynäkologisches Zentrum Bonn
    Bonn, North Rhine-Westphalia 53111, Germany
  • Frauenärzte am Schloss Borbeck
    Essen, North Rhine-Westphalia 45355, Germany
  • Medplus Nordrhein
    Krefeld, North Rhine-Westphalia 47799, Germany
  • Praxis f. Gynäkologie und Geburtshilfe
    Bernburg, Saxony-Anhalt 6406, Germany
  • Frauenarztpraxis Dr. Inka Kiesche
    Halle, Saxony-Anhalt 6110, Germany
  • Klinische Forschung Berlin-Mitte GmbH
    Berlin, 10117, Germany
  • Axon Kft.
    Kecskemét, Bács-Kiskun county 6000, Hungary
  • Rub-Int Noi Egeszsegcentrum
    Székesfehérvár, Fejér 8000, Hungary
  • Debreceni Egyetem Klinikai Kozpont
    Debrecen, Hajdú-Bihar 4032, Hungary
  • Szabolcs Szatmr Bereg County University Teaching Hospital | Andras Jasa Teaching Hospital - Oncology
    Nyíregyháza, Szabolcs-Szatmár-Bereg 4400, Hungary
  • University College Hospital Galway
    Galway, Connacht H91YR71, Ireland
  • St Vincents University Hospital
    Dublin, Leinster D04 TC63, Ireland
  • Mater Misericordiae University Hospital
    Dublin, Leinster D07R2WY, Ireland
  • St James' Hospital
    Dublin, Leinster D08NHY1, Ireland
  • Cork University Hospital
    Cork, Munster T12DC4A, Ireland
  • University Hospital Waterford
    Waterford, Munster X91 ER8E, Ireland
  • Assuta Ashdod Public Hospital (R.A)
    Ashdod, 7747629, Israel
  • Hadassah Hebrew University Hospital Ein Kerem
    Jerusalem, 9112001, Israel
  • Meir Medical Center
    Kfar Saba, 4428164, Israel
  • Health Corporation of Galilee Medical Center
    Nahariya, 2210001, Israel
  • Chaim Sheba Medical Center
    Ramat Gan, 5266202, Israel
  • Tel- Aviv Sourasky Medical Center - Nephrology
    Tel Aviv, 6492601, Israel
  • Azienda Ospedaliera Universitaria Federico II Di Napoli - DAI Materno Infantile
    Naples, Campania 80131, Italy
  • Azienda Ospedaliero Universitaria di Modena_Policlinico - Oncologia
    Modena, Emilia-Romagna 41124, Italy
  • Fondazione Policlinico Universitario Agostino Gemelli IRCCS - UOC Ginecologia Oncologica
    Rome, Lazio 00168, Italy
  • IRCCS Ospedale Policlinico San Martino - Clinica ostetrica e ginecologica
    Genoa, Liguria 16132, Italy
  • Istituto Europeo di Oncologia s.r.l - Ginecologia Preventiva
    Milan, Lombardy 20141, Italy
  • Fondazione IRCCS Policlinico San Matteo - Ostetricia e Ginecologia
    Pavia, Lombardy 27100, Italy
  • Azienda Ospedaliera Ordine Mauriziano Di Torino - Ostetricia e Ginecologia
    Turin, Piedmont 10128, Italy
  • Careggi University Hospital - Ostetricia e Ginecologia
    Florence, Tuscany 50134, Italy
  • Azienda Ospedaliera Universitaria Integrata Verona_Borgo Trento - Ostetricia e Ginecologia B
    Verona, Veneto 37126, Italy
  • Kazakh Institute of Oncology and Radiology - Department of Gynecology
    Almaty, Almaty Region 640000, Kazakhstan
  • Multidisciplinary Medical Center of the Akimat of Astana - Department of Chemotherapy No1
    Astana, Aqmola 010000, Kazakhstan
  • Gabinet Ginekologiczny Janusz Tomaszewski
    Bialystok, 15-224, Poland
  • CLINICAL MEDICAL RESEARCH Sp. z o. o.
    Katowice, 40-156, Poland
  • NZOZ MEDEM Wilk Sp. j.
    Katowice, 40-301, Poland
  • Pratia McM Kraków
    Krakow, 30-727, Poland
  • Prywatny Gabinet Lekarski Ginekologia, Poloznictwo i Ultr.
    Lodz, 90-602, Poland
  • Salve Medica Sp. z o.o. SP.K.
    Lodz, 91-211, Poland
  • Centrum Medyczne Pratia Poznan
    Skorzewo, 60-185, Poland
  • Centrum Badawcze Wspolczesnej Terapii
    Warsaw, 02-679, Poland
  • Luz Saude | Hospital Beatriz Angelo - Centro de Investigacao Clinica
    Loures, Lisbon District 2674-514, Portugal
  • Unidade Local de Saúde de Braga E.P.E. - Centro Clínico Académico de Braga - Serviço de Ginecologia
    Braga, 4710-243, Portugal
  • Unidade Local de Saúde de Coimbra, E.P.E. - Hospitais da Universidade de Coimbra - Serviço de Ginecologia
    Coimbra, 3000-075, Portugal
  • Fundacao Champalimaud | Centro Clinico Champalimaud - Unidade Investigacao Clinica
    Lisbon, 1400-038, Portugal
  • Unidade Local De Saúde De Lisboa Ocidental E.P.E.
    Lisbon, 1449-005, Portugal
  • Luz Saude | Hospital da Luz Lisboa - Centro de Investigacao Clinica
    Lisbon, 1500-650, Portugal
  • CHULN - H. Sta.Maria (Centro de Investigacao Clinica)
    Lisbon, 1649-035, Portugal
  • Centro Hospitalar Universitario do Porto
    Porto, 4050-651, Portugal
  • Companhia Uniao Fabril | Hospital CUF Porto - Clinical Trials Department
    Porto, 4100-180, Portugal
  • CHUSJ - Hospital Sao Joao
    Porto, 4200-319, Portugal
  • Sc Oncolab Srl
    Craiova, Dolj 200385, Romania
  • S.C. Centrul Medical de Diagnostic si Tratament Ambulator Neomed SRL
    Brasov, 500283, Romania
  • S.C. Quantum Medical Center SRL
    Bucharest, 012071, Romania
  • Spitalul Clinic Filantropia
    Bucharest, 11132, Romania
  • S.C Ovidius Clinical Hospital SRL - Oncology Department
    Ovidiu, 905900, Romania
  • Complexo Hospitalario Universitario De Santiago | Oncologia
    Santiago de Compostela, A Coruña 15706, Spain
  • La Zarzuela University Hospital | Ginecologia
    Aravaca, Madrid 28023, Spain
  • Hospital del Mar | Ginecologia
    Barcelona, 08003, Spain
  • Hospital Universitario Virgen De Las Nieves | Oncologia Medica
    Granada, 18014, Spain
  • Hospital General Universitario Gregorio Maranon | Oncologia
    Madrid, 28009, Spain
  • Hospital Universitario Virgen Del Rocio S.L. | Oncologia
    Seville, 41013, Spain
  • Hospital Clinico Universitario De Valencia | Ginecologia
    Valencia, 46010, Spain
  • Hospital General Universitario De Valencia | Ginecologia
    Valencia, 46014, Spain
  • Imperial College Healthcare NHS Trust| Queen Charlotte's and Chelsea Hospital - Gynaecology
    London, Greater London W12 0NN, United Kingdom
  • Liverpool Women's NHS Foundation Trust | Liverpool Women's Hospital - Gynaecology
    Liverpool, Merseyside L8 7SS, United Kingdom
  • NHS Greater Glasgow and Clyde | Glasgow Royal Infirmary - Gynaecology
    Glasgow, Scotland G4 0SF, United Kingdom

Showing the first 100 of 102 sites across 16 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Cardoso F, Parke S, Brennan DJ, Briggs P, Donders G, Panay N, Haseli-Mashhadi N, Block M, Caetano C, Francuski M, Haberland C, Laapas K, Seitz C, Zuurman L. Elinzanetant for Vasomotor Symptoms from Endocrine Therapy for Breast Cancer. N Engl J Med. 2025 Aug 21;393(8):753-763. doi: 10.1056/NEJMoa2415566. Epub 2025 Jun 2. PubMed 40454634 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — There are no current plans to share data. Interested researchers can use www.vivli.org to request access to anonymized patient-level data and supporting documents from clinical studies to conduct research. Information on the Bayer criteria for listing studies and other relevant information is provided in the member section of the portal.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2022 to primary completion in Jan 2024, 15 months.

Results were first posted in Oct 2025, 1 year 9 months after primary completion. A results delay was requested in Jan 2025.

Of 23 phase 3 interventional studies under Hot Flashes, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 29. This study's 15 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 17, 2022
First posted
Oct 20, 2022
StartActual
Oct 14, 2022
Primary completionActual
Jan 29, 2024
CompletionEst.
Jun 5, 2028
Results delay requested
Jan 3, 2025
Results first posted
Oct 29, 2025
Last update
Jul 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05587296
Lead sponsor
Bayer
Responsible party
Sponsor
First posted
Oct 20, 2022
Start date
Oct 14, 2022
Primary completion
Jan 29, 2024
Completion
Jun 5, 2028 (estimated)
Results posted
Oct 29, 2025
Last update
Jul 9, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Elinzanetant

Start the discussion